ArticleMedical oncology (Northwood, London, England)2013
The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Kinesin Spindle Protein (KIF11) in Mitosis and Cancer.International journal of molecular sciences · 2025Review
- HELLS Knockdown Inhibits the Malignant Progression of Lung Adenocarcinoma Via Blocking Akt/CREB Pathway by Downregulating KIF11.Molecular biotechnology · 2025Article
- The Kinesin Eg5 Inhibitor K858 Enhances Radiosensitivity in Esophageal Squamous Cell Carcinoma and Affects the Expression of Epithelial-mesenchymal Transition Related Markers:Anti-cancer agents in medicinal chemistry · 2025Article
- Integrated Machine Learning and Chemoinformatics-Based Screening of Mycotic Compounds against Kinesin Spindle ProteinEg5 for Lung Cancer Therapy.Molecules (Basel, Switzerland) · 2022Article
- Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers.Cancer science · 2021Article
- Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.Oncotarget · 2021Article
- KIF11 Promotes Proliferation of Hepatocellular Carcinoma among Patients with Liver Cancers.BioMed research international · 2021Article
- Identification of Metastasis-Associated Biomarkers in Synovial Sarcoma Using Bioinformatics Analysis.Frontiers in genetics · 2020Article
- KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer.Cancer research and treatment · 2019Article
- High kinesin family member 11 expression predicts poor prognosis in patients with clear cell renal cell carcinoma.Journal of clinical pathology · 2019Article
- MicroRNA-186-5p represses neuroblastoma cell growth via downregulation ofAmerican journal of translational research · 2019Article
- S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.Oncology letters · 2018Article
- Cancer drug therapy and stochastic modeling of "nano-motors".International journal of nanomedicine · 2018Article
- Kinesin family member 11 contributes to the progression and prognosis of human breast cancer.Oncology letters · 2017Article
- High Eg5 expression predicts poor prognosis in breast cancer.Oncotarget · 2017Article
- Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients.Disease markers · 2017Article
- KSP inhibitor SB743921 inhibits growth and induces apoptosis of breast cancer cells by regulating p53, Bcl-2, and DTL.Anti-cancer drugs · 2016Article
- Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Overexpression of Eg5 correlates with high grade astrocytic neoplasm.Journal of neuro-oncology · 2016Article
- Recent findings and future directions for interpolar mitotic kinesin inhibitors in cancer therapy.Future medicinal chemistry · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eg5 is a member of the kinesin family of proteins, which associates with bipolar spindle formation in dividing tumor cells during mitosis. The aim of our study is to investigate the prognostic role of Eg5 expression in patients with renal cell carcinoma (RCC). RCC tissue specimens from 164 consecutively treated patients who underwent surgery between 2005 and 2011 were evaluated. The Eg5 expression was determined by immunohistochemistry, and correlated with clinicopathological parameters. The prognostic significance of Eg5 expression was explored using the univariate and multivariate survival analysis of 164 patients who were followed; one hundred and sixty-four tissue specimens "of patients" who were regularly followed with the mean 35.8 months (from 5 to 80 months). The expression of Eg5 was significantly associated with tumor nuclear grade (P = 0.019) and stage (P = 0.007), as well as tumor size (P = 0.033). In univariate analysis, Eg5 overexpression showed unfavorable influence on recurrence-free survival with statistical significance (P = 0.003). Clinical stage, nuclear grade and tumor size also showed strong statistical relation with adverse recurrence-free survival (P < 0.001). Multivariate analysis revealed that tumor stage, nuclear grade and Eg5 reactivity (P < 0.001, P = 0.002, P = 0.032) were identified as independent prognostic factors for recurrence-free survival in patients with RCC. In our opinion, the result of this study proved the relationship between Eg5 expression and worse clinical outcome in RCC. This finding suggested that Eg5 served as a prognostic factor, which could be useful to predict cancer evolution and provide appropriate treatments for RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.